{"id":859311,"date":"2025-06-10T17:58:20","date_gmt":"2025-06-10T21:58:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/"},"modified":"2025-06-10T17:58:20","modified_gmt":"2025-06-10T21:58:20","slug":"philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/","title":{"rendered":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales <\/em><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">OTELFINGEN, Switzerland, June  10, 2025  (GLOBE NEWSWIRE) &#8212; Philochem AG (&#8220;Philochem\u201d), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (\u201cRayzeBio\u201d), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.<\/p>\n<p align=\"justify\">OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with <sup>225<\/sup>Ac-OncoACP3 are ongoing.<\/p>\n<p align=\"justify\">\n        <strong>Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented:<\/strong> \u201cWe are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Ben Hickey, President, RayzeBio commented: <\/strong>\u201cThis collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.\u201d<\/p>\n<p align=\"justify\">Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3.<\/p>\n<p align=\"justify\">The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025.<\/p>\n<p align=\"justify\">For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel.<\/p>\n<p align=\"justify\">\n        <strong>About Philogen group <\/strong>\n      <\/p>\n<p align=\"justify\">Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen\u2019s mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group\u2019s drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases.<\/p>\n<p align=\"justify\">\n        <strong>FOR MORE INFORMATION<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Philogen &#8211; Investor Relations <\/strong>\n      <\/p>\n<p align=\"justify\">IR@philogen.com &#8211; Emanuele Puca | Investor Relations<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MjExODQ1NWQtMzg3OC00OTVhLWFkODctMzJlZWU4YzgyZDUzLTEyNzUyMDEtMjAyNS0wNi0xMC1lbg==\/tiny\/Philogen-S-p-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Philochem AG (&#8220;Philochem\u201d), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (\u201cRayzeBio\u201d), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859311","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Philochem AG (&#8220;Philochem\u201d), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (\u201cRayzeBio\u201d), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation &hellip; Continue reading &quot;Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T21:58:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties\",\"datePublished\":\"2025-06-10T21:58:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/\",\"name\":\"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\",\"datePublished\":\"2025-06-10T21:58:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/","og_locale":"en_US","og_type":"article","og_title":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk","og_description":"Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Philochem AG (&#8220;Philochem\u201d), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (\u201cRayzeBio\u201d), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation &hellip; Continue reading \"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T21:58:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties","datePublished":"2025-06-10T21:58:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/","name":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==","datePublished":"2025-06-10T21:58:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEwMTk0MCM0MDIxNTYzODkjMjI2MzY1MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philochem-ag-announces-the-licensing-of-worldwide-rights-to-oncoacp3-a-novel-radiopharmaceutical-therapeutic-and-diagnostic-agent-targeting-prostate-cancer-to-rayzebio-a-bristol-myers-squibb-compan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859311"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859311\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}